Laquinimod (ABR-215062) sodium 是一种可口服的羧酰胺衍生物，是一种有效的免疫调节剂，可防止中枢神经系统的神经变性和炎症。Laquinimod sodium 减少星形胶质细胞NF-Κb的活化以防止铜酮 (Cuprizone) 诱导的脱髓鞘。Laquinimod sodium 具有用于多发性硬化症 (MS；RRMS 或 CPMS) 的复发缓解 (RR) 和慢性进行性 (CP) 形式以及神经退行性疾病研究的潜力。

Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research [1] [2] [3] [4].

Laquinimod sodium reverses EAE and inhibits pathogenic T cell immune responses. Laquinimod reverses RR-EAE and inhibits inflammatory T cell responses via a direct effect on myeloid APC. Laquinimod alters myeloid APC subsets and inhibits Th1 and Th17 polarization of myelin-specific T cells. Laquinimod-induced type II (M2) monocytes reverse established EAE [1]. Laquinimod modulates the phenotype of B cells of healthy donors. Laquinimod modulates expression of markers related to regulatory capacity in B cells of RRMS patients. Laquinimod reduces IFNγ cytokine expression in CD4 + T cells [2].

Laquinimod sodium treatment inhibits donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment alters subpopulations of myeloid antigen presenting cells (APC) that include a decrease in CD11c + CD11b + CD4 + dendritic cells (DC) and an elevation of CD11b hi Gr1 hi monocytes [1].

248282-07-7

C19H17ClN2NaO3

379.79

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years